MA53831A - Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques - Google Patents

Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques

Info

Publication number
MA53831A
MA53831A MA053831A MA53831A MA53831A MA 53831 A MA53831 A MA 53831A MA 053831 A MA053831 A MA 053831A MA 53831 A MA53831 A MA 53831A MA 53831 A MA53831 A MA 53831A
Authority
MA
Morocco
Prior art keywords
aggregation
reducing
methods
specific antibodies
antibodies
Prior art date
Application number
MA053831A
Other languages
English (en)
Inventor
Joon Huh
Bharadwaj Jagannathan
Daxian Shan
Michael Treuheit
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA53831A publication Critical patent/MA53831A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA053831A 2018-10-01 2019-09-27 Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques MA53831A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862739542P 2018-10-01 2018-10-01

Publications (1)

Publication Number Publication Date
MA53831A true MA53831A (fr) 2022-01-05

Family

ID=70055398

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053831A MA53831A (fr) 2018-10-01 2019-09-27 Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques

Country Status (15)

Country Link
US (1) US20240336685A1 (fr)
EP (1) EP3860567A4 (fr)
JP (2) JP7676304B2 (fr)
KR (1) KR20210070314A (fr)
CN (1) CN112789028A (fr)
AU (1) AU2019351715B2 (fr)
BR (1) BR112021006220A2 (fr)
CA (1) CA3112655A1 (fr)
CL (1) CL2021000827A1 (fr)
EA (1) EA202190955A1 (fr)
IL (1) IL281621A (fr)
MA (1) MA53831A (fr)
MX (1) MX2021003628A (fr)
SG (1) SG11202102995PA (fr)
WO (1) WO2020072306A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190189A1 (ar) * 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
US20230348596A1 (en) * 2020-08-24 2023-11-02 Amgen Inc. Pharmaceutical formulation
EP4214233A1 (fr) * 2020-09-16 2023-07-26 Amgen Inc. Méthodes d'administration de doses thérapeutiques de molécules bispécifiques activant les lymphocytes t pour le traitement du cancer
WO2022060878A1 (fr) * 2020-09-16 2022-03-24 Amgen Inc. Méthodes de traitement du cancer de la prostate
US20240316194A1 (en) * 2021-06-30 2024-09-26 Amgen Inc. Method of reconstituting lyophilized formulation
WO2024059675A2 (fr) * 2022-09-14 2024-03-21 Amgen Inc. Composition de stabilisation de molécule bispécifique
WO2025101672A1 (fr) 2023-11-06 2025-05-15 City Of Hope Méthodes faisant appel à des virus oncolytiques exprimant des engageurs de lymphocytes t cd19t et bispécifiques
WO2026002279A1 (fr) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Peptide de masque, substrat clivable, anticorps multispécifiques et leurs utilisations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2225275A4 (fr) 2007-11-28 2013-04-03 Medimmune Llc Formulation de protéine
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
CN104093744A (zh) 2011-10-11 2014-10-08 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
CN104780940B (zh) * 2012-11-06 2017-11-07 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
DK3406633T3 (da) 2013-07-25 2022-03-28 Cytomx Therapeutics Inc Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
AU2015257798C1 (en) * 2014-05-07 2020-10-22 Takeda Pharmaceutical Company Limited Liquid formulation comprising GM-CSF neutralizing compound
WO2016036678A1 (fr) 2014-09-02 2016-03-10 Medimmune, Llc Formulations d'anticorps bispécifiques
EP3226896A1 (fr) * 2014-12-02 2017-10-11 Biogen MA Inc. Procédés et compositions de lutte contre l'agrégation d'anticorps
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JP2019505520A (ja) * 2016-01-13 2019-02-28 ゲンマブ エー／エス 抗体およびその薬物コンジュゲートの製剤
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
TN2018000266A1 (en) * 2016-02-03 2020-01-16 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
AU2018261951B2 (en) * 2017-05-05 2025-05-22 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
TWI827570B (zh) * 2017-12-11 2024-01-01 美商安進公司 雙特異性抗體產品之連續製造製程

Also Published As

Publication number Publication date
AU2019351715A1 (en) 2021-04-22
JP2025160922A (ja) 2025-10-23
SG11202102995PA (en) 2021-04-29
EP3860567A4 (fr) 2022-07-06
AU2019351715B2 (en) 2025-11-27
CA3112655A1 (fr) 2020-04-09
WO2020072306A1 (fr) 2020-04-09
CL2021000827A1 (es) 2021-10-15
EA202190955A1 (ru) 2021-08-17
JP2022512569A (ja) 2022-02-07
JP7676304B2 (ja) 2025-05-14
IL281621A (en) 2021-05-31
KR20210070314A (ko) 2021-06-14
CN112789028A (zh) 2021-05-11
BR112021006220A2 (pt) 2021-07-06
MX2021003628A (es) 2021-05-27
EP3860567A1 (fr) 2021-08-11
US20240336685A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
MA53831A (fr) Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA52884A (fr) Anticorps anti-il-11
EP3723803A4 (fr) Anticorps anti-trem2 et méthodes associées
MA46643A (fr) Méthodes et compositions pour le mappage d'arn
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
EP3658589C0 (fr) Anticorps anti-sirp-alpha et méthodes associées
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3423044A4 (fr) Nanovaccin activant sting pour l'immunothérapie
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
EP3359573A4 (fr) Marquage d'anticorps
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3692072A4 (fr) Anticorps anti-hla-dq2.5
EP3752536A4 (fr) Anticorps anti-her2
EP3397288A4 (fr) Méthodes pour diminuer l'expression de l'ataxine-2
EP3399992A4 (fr) Anticorps autoréticulants
IL262588A (en) Humanized anti-basigin antibodies and the use thereof
EP3831851A4 (fr) Anticorps anti-btla
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
EP3452084A4 (fr) Anticorps anti-kv 1.3 et procédés pour les produire et les utiliser
MA50654A (fr) Anticorps anti-pacap
MA49257A (fr) Anticorps anti-trkb
MA49781A (fr) Expression directe d'anticorps